0000950170-23-028600.txt : 20230616 0000950170-23-028600.hdr.sgml : 20230616 20230616160738 ACCESSION NUMBER: 0000950170-23-028600 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230614 ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230616 DATE AS OF CHANGE: 20230616 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kezar Life Sciences, Inc. CENTRAL INDEX KEY: 0001645666 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473366145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38542 FILM NUMBER: 231021099 BUSINESS ADDRESS: STREET 1: 4000 SHORELINE COURT, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-822-5600 MAIL ADDRESS: STREET 1: 4000 SHORELINE COURT, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 kzr-20230614.htm 8-K 8-K
--12-31false000164566600016456662023-06-142023-06-14

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 14, 2023

 

 

Kezar Life Sciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-38542

47-3366145

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

4000 Shoreline Court, Suite 300

 

South San Francisco, California

 

94080

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 650 822-5600

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.001 par value

 

KZR

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

Item 3.03 Material Modification to Rights of Security Holders.

On June 14, 2023, following receipt of the affirmative vote from the holders of a majority of the outstanding shares of common stock of Kezar Life Sciences, Inc. (the “Company”) at its 2023 annual meeting of stockholders (the “Annual Meeting”), the Company filed a certificate of amendment to the Company’s amended and restated certificate of incorporation (the “Certificate Amendment”) with the Secretary of State of the State of Delaware to increase the authorized number of total shares of all classes of stock that the Company has authority to issue from 135,000,000 shares to 260,000,000 shares, consisting of two classes: (1) 250,000,000 shares of common stock, $0.0001 par value per share, and (2) 10,000,000 shares of preferred stock, $0.001 par value per share. The Certificate Amendment became effective immediately upon filing.

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

As described under Item 3.03, on June 14, 2023, the Company filed the Certificate Amendment with the Secretary of State of the State of Delaware. The information in Item 3.03 is incorporated by reference into this Item 5.03.

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 14, 2023, the Company held its Annual Meeting. The final results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeting are set forth below. The proposals set forth below are described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 27, 2023.

Proposal 1: The Company’s stockholders elected the three nominees of the Company’s board of directors to serve as Class II directors until the 2026 annual meeting of stockholders, or until their successors are duly elected and qualified, by the votes set forth in the table below:

Nominee

Votes For

Votes Withheld

Broker Non-Votes

Franklin Berger

33,265,209

22,578,381

10,395,798

Graham Cooper

55,391,603

451,987

10,395,798

Micki Klearman, M.D.

51,104,468

4,739,122

10,395,798

Proposal 2: The Company’s stockholders ratified the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 by the votes set forth in the table below:

Votes For

Votes Against

Abstain

66,231,058

5,202

3,128

Proposal 3: The Company’s stockholders approved an amendment to the Company's amended and restated certificate of incorporation to increase the number of authorized shares of common stock by the votes set forth in the table below:

Votes For

Votes Against

Abstain

65,253,861

890,792

94,735

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit No.

Description

3.1

Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

KEZAR LIFE SCIENCES, INC.

 

 

 

 

Dated:

June 16, 2023

By:

/s/ Marc L. Belsky

 

 

 

Marc L. Belsky
Chief Financial Officer and Secretary

 

 EX-3.1 2 kzr-ex3_1.htm EX-3.1 EX-3.1

Exhibit 3.1

 

CERTIFICATE OF AMENDMENT TO THE

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

OF KEZAR LIFE SCIENCES, INC.

Kezar Life Sciences, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware, does hereby certify as follows:

First: The name of the Corporation is Kezar Life Sciences, Inc.

Second: The date of filing the original Certificate of Incorporation of the Corporation with the Secretary of State of the State of Delaware was February 19, 2015.

Third: The Board of Directors of the Corporation, acting in accordance with the provisions of Sections 141 and 242 of the General Corporation Law of the State of Delaware, adopted resolutions amending its Amended and Restated Certificate of Incorporation as follows:

The first paragraph of Article IV is hereby deleted in its entirety and replaced as follows:

“A. The Corporation is authorized to issue two classes of stock to be designated, respectively, “Common Stock” and “Preferred Stock.” The total number of shares which the Corporation is authorized to issue is two hundred sixty million (260,000,000) shares. Two hundred fifty million (250,000,000) shares shall be Common Stock, each having a par value of one-tenth of one cent ($0.001) and ten million (10,000,000) shares shall be Preferred Stock, each having a par value of one-tenth of one cent ($0.001).”

Fourth: The foregoing amendment was submitted to the stockholders of the Corporation for their approval and was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.

[Signature Page Follows]

 

 

In Witness Whereof, Kezar Life Sciences, Inc. has caused this Certificate of Amendment to be signed by its Chief Executive Officer on this 14th day of June, 2023.

 

 

 

 

 

 

 

KEZAR LIFE SCIENCES, INC.

 

 

 

 

 

 

By:

/s/ John Fowler

 

 

 

John Fowler
Chief Executive Officer

 

 EX-101.PRE 3 kzr-20230614_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 4 kzr-20230614.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 kzr-20230614_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Current Fiscal Year End Date Document Period End Date Document Type Entity Address, Address Line One Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity Ex Transition Period Securities Act File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document And Entity Information
Jun. 14, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Current Fiscal Year End Date --12-31
Document Period End Date Jun. 14, 2023
Entity Registrant Name Kezar Life Sciences, Inc.
Entity Central Index Key 0001645666
Entity Emerging Growth Company true
Securities Act File Number 001-38542
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 47-3366145
Entity Address, Address Line One 4000 Shoreline Court, Suite 300
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code 650
Local Phone Number 822-5600
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period true
Title of 12(b) Security Common Stock, $0.001 par value
Trading Symbol KZR
Security Exchange Name NASDAQ
XML 7 kzr-20230614_htm.xml IDEA: XBRL DOCUMENT 0001645666 2023-06-14 2023-06-14 --12-31 false 0001645666 8-K 2023-06-14 Kezar Life Sciences, Inc. DE 001-38542 47-3366145 4000 Shoreline Court, Suite 300 South San Francisco CA 94080 650 822-5600 false false false false Common Stock, $0.001 par value KZR NASDAQ true true EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.kezarlifesciences.com/20230614/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports kzr-20230614.htm kzr-20230614.xsd kzr-20230614_lab.xml kzr-20230614_pre.xml kzr-ex3_1.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "kzr-20230614.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "kzr-20230614.htm" ] }, "labelLink": { "local": [ "kzr-20230614_lab.xml" ] }, "presentationLink": { "local": [ "kzr-20230614_pre.xml" ] }, "schema": { "local": [ "kzr-20230614.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "kzr", "nsuri": "http://www.kezarlifesciences.com/20230614", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "kzr-20230614.htm", "contextRef": "C_3d49f17e-a266-49ee-9a70-38cb53f30ffa", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.kezarlifesciences.com/20230614/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "kzr-20230614.htm", "contextRef": "C_3d49f17e-a266-49ee-9a70-38cb53f30ffa", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.kezarlifesciences.com/20230614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.kezarlifesciences.com/20230614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.kezarlifesciences.com/20230614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.kezarlifesciences.com/20230614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.kezarlifesciences.com/20230614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.kezarlifesciences.com/20230614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.kezarlifesciences.com/20230614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.kezarlifesciences.com/20230614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.kezarlifesciences.com/20230614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.kezarlifesciences.com/20230614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.kezarlifesciences.com/20230614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.kezarlifesciences.com/20230614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Securities Act File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.kezarlifesciences.com/20230614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.kezarlifesciences.com/20230614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.kezarlifesciences.com/20230614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.kezarlifesciences.com/20230614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.kezarlifesciences.com/20230614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.kezarlifesciences.com/20230614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.kezarlifesciences.com/20230614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.kezarlifesciences.com/20230614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.kezarlifesciences.com/20230614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.kezarlifesciences.com/20230614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.kezarlifesciences.com/20230614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.kezarlifesciences.com/20230614/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0000950170-23-028600-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-028600-xbrl.zip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end